Microarray and deep sequencing cross-platform analysis of the mirRNome and isomiR variation in response to epidermal growth factor

BMC Genomics

Volumn 14, Issue 1, 2013, Pages

  Llorens, Franc ^a,b,c,d,e   Hummel, Manuela ^a,b   Pantano, Lorena ^a,b,f,g   Pastor, Xavier ^a,b,g   Vivancos, Ana ^a,b,h   Castillo, Ester ^a,b   Mattlin, Heidi ^a,b,i   Ferrer, Anna ^a,b   Ingham, Matthew ^a,b,i   Noguera, Marc ^g,j   Kofler, Robert ^a,b,k,l   Dohm, Juliane C ^a,b,k   Pluvinet, Raquel ^g   Bayés, Mònica ^a,b,i   Himmelbauer, Heinz ^a,b   del Rio, José A ^c,d,e   Martí, Eulàlia ^a,b,f   Sumoy, Lauro ^a,b,g  

^a CENTRE FOR GENOMIC REGULATION CRG   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c INSTITUTE FOR BIOENGINEERING OF CATALONIA IBEC   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^f CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^g Institute of Predictive and Personalized Medicine of Cancer (IMPPC)   (Spain)

^h VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

ⁱ Parc Cientific de Barcelona   (Spain)

^j IrsiCaixa Foundation   (Spain)

^k MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^l UNIVERSITY OF VETERINARY MEDICINE   (Austria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; MICRORNA; MICRORNA 132; MICRORNA 21; MICRORNA 215; MICRORNA 221; MICRORNA 222; MICRORNA 29A; MICRORNA 29B; MICRORNA 31; MICRORNA 7; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ARTICLE; BIOINFORMATICS; CONTROLLED STUDY; DEEP SEQUENCING; GENE CONTROL; GENE FUNCTION; GENE IDENTIFICATION; GENE SEQUENCE; GENE SILENCING; GENE TARGETING; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOME; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MIRNOME; NUCLEOTIDE SEQUENCE; PREDICTION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EDITING; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; VALIDATION STUDY;

EPIDERMAL GROWTH FACTOR; GENE SILENCING; GENE TARGETING; GENOMICS; HELA CELLS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SEQUENCE ANALYSIS, RNA; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84878349081     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-14-371     Document Type: Article

References (82)

1. Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW, Yokoyama S. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003, 12(3):541-552. 10.1016/S1097-2765(03)00350-2, 14527402.
2. Henson ES, Gibson SB. Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy. Cell Signal 2006, 18(12):2089-2097. 10.1016/j.cellsig.2006.05.015, 16815674.
3. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000, 19(13):3159-3167. 10.1093/emboj/19.13.3159, 313958, 10880430.
4. Bianco R, Gelardi T, Damiano V, Ciardiello F, Tortora G. Rational bases for the development of EGFR inhibitors for cancer treatment. Int J Biochem Cell Biol 2007, 39(7-8):1416-1431.
5. Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P, Mann M. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 2006, 127(3):635-648. 10.1016/j.cell.2006.09.026, 17081983.
6. Amit I, Citri A, Shay T, Lu Y, Katz M, Zhang F, Tarcic G, Siwak D, Lahad J, Jacob-Hirsch J, Amariglio N, Vaisman N, Segal E, Rechavi G, Alon U, Mills GB, Domany E, Yarden Y. A module of negative feedback regulators defines growth factor signaling. Nat Genet 2007, 39(4):503-512. 10.1038/ng1987, 17322878.
7. Avraham R, Sas-Chen A, Manor O, Steinfeld I, Shalgi R, Tarcic G, Bossel N, Zeisel A, Amit I, Zwang Y, Enerly E, Russnes HG, Biagioni F, Mottolese M, Strano S, Blandino G, Borresen-Dale AL, Pilpel Y, Yakhini Z, Segal E, Yarden Y. EGF decreases the abundance of microRNAs that restrain oncogenic transcription factors. Sci Signal 2010, 3(124):ra43. 10.1126/scisignal.2000876, 20516477.
8. Singh SK, Pal Bhadra M, Girschick HJ, Bhadra U. MicroRNAs-micro in size but macro in function. FEBS J 2008, 275(20):4929-4944. 10.1111/j.1742-4658.2008.06624.x, 18754771.
9. Chang TC, Mendell JT. microRNAs in vertebrate physiology and human disease. Annu Rev Genomics Hum Genet 2007, 8:215-239. 10.1146/annurev.genom.8.080706.092351, 17506656.
10. Hammell M, Long D, Zhang L, Lee A, Carmack CS, Han M, Ding Y, Ambros V. mirWIP: microRNA target prediction based on microRNA-containing ribonucleoprotein-enriched transcripts. Nat Methods 2008, 5(9):813-819. 10.1038/nmeth.1247, 3092588, 19160516.
11. Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE, Green AR, Ellis IO, Tavare S, Caldas C, Miska EA. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 2007, 8(10):R214. 10.1186/gb-2007-8-10-r214, 2246288, 17922911.
12. Davalos V, Esteller M. MicroRNAs and cancer epigenetics: a macrorevolution. Curr Opin Oncol 2010, 22(1):35-45. 10.1097/CCO.0b013e328333dcbb, 19907325.
13. Cherqui D, Laurent A, Mocellin N, Tayar C, Luciani A, Van Nhieu JT, Decaens T, Hurtova M, Memeo R, Mallat A, Duvoux C. Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. Ann Surg 2009, 250(5):738-746. 10.1097/SLA.0b013e3181bd582b, 19801927.
14. Deng S, Calin GA, Croce CM, Coukos G, Zhang L. Mechanisms of microRNA deregulation in human cancer. Cell Cycle 2008, 7(17):2643-2646. 10.4161/cc.7.17.6597, 18719391.
15. Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol 2010, 11(4):252-263.
16. Llorens F, Hummel M, Pastor X, Ferrer A, Pluvinet R, Vivancos A, Castillo E, Iraola S, Mosquera AM, Gonzalez E, Lozano J, Ingham M, Dohm JC, Noguera M, Kofler R, del Rio JA, Bayes M, Himmelbauer H, Sumoy L. Multiple platform assessment of the EGF dependent transcriptome by microarray and deep tag sequencing analysis. BMC Genomics 2011, 12:326. 10.1186/1471-2164-12-326, 3141672, 21699700.
17. Hayashi T, Koyama N, Gresik EW, Kashimata M. Detection of EGF-dependent microRNAs of the fetal mouse submandibular gland at embryonic day 13. J Med Invest 2009, 56(Suppl):250-252.
18. Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon Y-J, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G, Engelman JA, Ono M, Rho JK, Cascione L, Volinia S, Nephew KP, Croce CM. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 2012, 18(1):74-82.
19. Dohm JC, Lottaz C, Borodina T, Himmelbauer H. Substantial biases in ultra-short read data sets from high-throughput DNA sequencing. Nucleic Acids Res 2008, 36(16):e105. 10.1093/nar/gkn425, 2532726, 18660515.
20. Robinson MD, Oshlack A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol 2010, 11(3):R25. 10.1186/gb-2010-11-3-r25, 2864565, 20196867.
21. Pantano L, Estivill X, Marti E. SeqBuster, a bioinformatic tool for the processing and analysis of small RNAs datasets, reveals ubiquitous miRNA modifications in human embryonic cells. Nucleic Acids Res 2010, 38(5):e34. 10.1093/nar/gkp1127, 2836562, 20008100.
22. Marti E, Pantano L, Banez-Coronel M, Llorens F, Minones-Moyano E, Porta S, Sumoy L, Ferrer I, Estivill X. A myriad of miRNA variants in control and Huntington's disease brain regions detected by massively parallel sequencing. Nucleic Acids Res 2010, 38(20):7219-7235. 10.1093/nar/gkq575, 2978354, 20591823.
23. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001, 98(9):5116-5121. 10.1073/pnas.091062498, 33173, 11309499.
24. Wettenhall JM, Smyth GK. limmaGUI: a graphical user interface for linear modeling of microarray data. Bioinformatics 2004, 20(18):3705-3706. 10.1093/bioinformatics/bth449, 15297296.
25. Hong F, Breitling R, McEntee CW, Wittner BS, Nemhauser JL, Chory J. RankProd: a bioconductor package for detecting differentially expressed genes in meta-analysis. Bioinformatics 2006, 22(22):2825-2827. 10.1093/bioinformatics/btl476, 16982708.
26. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001, 125(1-2):279-284.
27. Hsu SD, Lin FM, Wu WY, Liang C, Huang WC, Chan WL, Tsai WT, Chen GZ, Lee CJ, Chiu CM, Chien CH, Wu MC, Huang CY, Tsou AP, Huang HD. miRTarBase: a database curates experimentally validated microRNA-target interactions. Nucleic Acids Res 2011, 39(Database issue):D163-D169. 3013699, 21071411.
28. Raymond CK, Roberts BS, Garrett-Engele P, Lim LP, Johnson JM. Simple, quantitative primer-extension PCR assay for direct monitoring of microRNAs and short-interfering RNAs. RNA 2005, 11(11):1737-1744. 10.1261/rna.2148705, 1370860, 16244135.
29. Wieduwilt MJ, Moasser MM. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci 2008, 65(10):1566-1584. 10.1007/s00018-008-7440-8, 3060045, 18259690.
30. Skaftnesmo KO, Prestegarden L, Micklem DR, Lorens JB. MicroRNAs in tumorigenesis. Curr Pharm Biotechnol 2007, 8(6):320-325. 10.2174/138920107783018390, 18289039.
31. Zimmerman AL, Wu S. MicroRNAs, cancer and cancer stem cells. Cancer Lett 2011, 300(1):10-19. 10.1016/j.canlet.2010.09.019, 2991536, 20965651.
32. Fabbri M, Calin GA. Epigenetics and miRNAs in human cancer. Adv Genet 2010, 70:87-99.
33. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010, 9(10):775-789. 10.1038/nrd3179, 20885409.
34. Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 2006, 94(6):776-780. 10.1038/sj.bjc.6603023, 2361377, 16495913.
35. Adams BD, Claffey KP, White BA. Argonaute-2 expression is regulated by epidermal growth factor receptor and mitogen-activated protein kinase signaling and correlates with a transformed phenotype in breast cancer cells. Endocrinology 2009, 150(1):14-23. 2630894, 18787018.
36. Gillies JK, Lorimer IA. Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. Cell Cycle 2007, 6(16):2005-2009. 10.4161/cc.6.16.4526, 17721077.
37. Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, Hawkinson M, Lee J, Fine H, Chiocca EA, Lawler S, Purow B. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 2008, 68(10):3566-3572.
38. Giles KM, Barker A, Zhang PM, Epis MR, Leedman PJ. MicroRNA regulation of growth factor receptor signaling in human cancer cells. Methods Mol Biol 2011, 676:147-163.
39. Saydam O, Senol O, Wurdinger T, Mizrak A, Ozdener GB, Stemmer-Rachamimov AO, Yi M, Stephens RM, Krichevsky AM, Saydam N, Brenner GJ, Breakefield XO. miRNA-7 attenuation in Schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways. Cancer Res 2011, 71(3):852-861. 10.1158/0008-5472.CAN-10-1219, 3072568, 21156648.
40. Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, Leedman PJ. Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem 2009, 284(9):5731-5741.
41. Roccaro AM, Sacco A, Chen C, Runnels J, Leleu X, Azab F, Azab AK, Jia X, Ngo HT, Melhem MR, Burwick N, Varticovski L, Novina CD, Rollins BJ, Anderson KC, Ghobrial IM. microRNA expression in the biology, prognosis, and therapy of Waldenstrom macroglobulinemia. Blood 2009, 113(18):4391-4402.
42. Dangi-Garimella S, Yun J, Eves EM, Newman M, Erkeland SJ, Hammond SM, Minn AJ, Rosner MR. Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. EMBO J 2009, 28(4):347-358. 10.1038/emboj.2008.294, 2646152, 19153603.
43. Rahadiani N, Takakuwa T, Tresnasari K, Morii E, Aozasa K. Latent membrane protein-1 of Epstein-Barr virus induces the expression of B-cell integration cluster, a precursor form of microRNA-155, in B lymphoma cell lines. Biochem Biophys Res Commun 2008, 377(2):579-583. 10.1016/j.bbrc.2008.10.007, 18926796.
44. Chou YT, Lin HH, Lien YC, Wang YH, Hong CF, Kao YR, Lin SC, Chang YC, Lin SY, Chen SJ, Chen HC, Yeh SD, Wu CW. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer Res 2010, 70(21):8822-8831. 10.1158/0008-5472.CAN-10-0638, 20978205.
45. Zheng J, Xue H, Wang T, Jiang Y, Liu B, Li J, Liu Y, Wang W, Zhang B, Sun M. miR-21 downregulates the tumor suppressor P12(CDK2AP1) and stimulates cell proliferation and invasion. J Cell Biochem 2010, 112(3):872-80.
46. Jazbutyte V, Thum T. MicroRNA-21: from cancer to cardiovascular disease. Curr Drug Targets 2010, 11(8):926-935. 10.2174/138945010791591403, 20415649.
47. Papagiannakopoulos T, Shapiro A, Kosik KS. MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res 2008, 68(19):8164-8172.
48. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX, Shao JY. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008, 14(11):2348-2360. 10.1261/rna.1034808, 2578865, 18812439.
49. Dillhoff M, Liu J, Frankel W, Croce C, Bloomston M. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg 2008, 12(12):2171-2176. 10.1007/s11605-008-0584-x, 18642050.
50. Connolly E, Melegari M, Landgraf P, Tchaikovskaya T, Tennant BC, Slagle BL, Rogler LE, Zavolan M, Tuschl T, Rogler CE. Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Am J Pathol 2008, 173(3):856-864. 10.2353/ajpath.2008.080096, 2527078, 18688024.
51. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133(2):647-658.
52. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, Allgayer H. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008, 27(15):2128-2136. 10.1038/sj.onc.1210856, 17968323.
53. Tang Z, Bauer JA, Morrison B, Lindner DJ. Nitrosylcobalamin promotes cell death via S nitrosylation of Apo2L/TRAIL receptor DR4. Mol Cell Biol 2006, 26(15):5588-5594. 10.1128/MCB.00199-06, 1592761, 16847314.
54. Talotta F, Cimmino A, Matarazzo MR, Casalino L, De Vita G, D'Esposito M, Di Lauro R, Verde P. An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation. Oncogene 2009, 28(1):73-84. 10.1038/onc.2008.370, 18850008.
55. Schramedei K, Morbt N, Pfeifer G, Lauter J, Rosolowski M, Tomm JM, von Bergen M, Horn F, Brocke-Heidrich K. MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4. Oncogene 2011, 30(26):2975-85. 10.1038/onc.2011.15, 3134876, 21317927.
56. Kwak HJ, Kim YJ, Chun KR, Woo YM, Park SJ, Jeong JA, Jo SH, Kim TH, Min HS, Chae JS, Choi EJ, Kim G, Shin SH, Gwak HS, Kim SK, Hong EK, Lee GK, Choi KH, Kim JH, Yoo H, Park JB, Lee SH. Downregulation of Spry2 by miR-21 triggers malignancy in human gliomas. Oncogene 2011, 30(21):2433-42. 10.1038/onc.2010.620, 21278789.
57. Mott JL, Kobayashi S, Bronk SF, Gores GJ. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007, 26(42):6133-6140. 10.1038/sj.onc.1210436, 2432524, 17404574.
58. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, Volinia S, Guler G, Morrison CD, Chan KK, Marcucci G, Calin GA, Huebner K, Croce CM. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A 2007, 104(40):15805-15810. 10.1073/pnas.0707628104, 2000384, 17890317.
59. Garzon R, Heaphy CE, Havelange V, Fabbri M, Volinia S, Tsao T, Zanesi N, Kornblau SM, Marcucci G, Calin GA, Andreeff M, Croce CM. MicroRNA 29b functions in acute myeloid leukemia. Blood 2009, 114(26):5331-5341. 10.1182/blood-2009-03-211938, 2796138, 19850741.
60. Santanam U, Zanesi N, Efanov A, Costinean S, Palamarchuk A, Hagan JP, Volinia S, Alder H, Rassenti L, Kipps T, Croce CM, Pekarsky Y. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc Natl Acad Sci U S A 2010, 107(27):12210-12215. 10.1073/pnas.1007186107, 2901490, 20566844.
61. Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, Jia WH, Zhuang SM. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010, 51(3):836-845.
62. Nguyen T, Kuo C, Nicholl MB, Sim MS, Turner RR, Morton DL, Hoon DS. Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics 2011, 6(3):388-394. 10.4161/epi.6.3.14056, 3063331,3063331, 21081840.
63. Wu J, Xie X. Comparative sequence analysis reveals an intricate network among REST, CREB and miRNA in mediating neuronal gene expression. Genome Biol 2006, 7(9):R85. 10.1186/gb-2006-7-9-r85, 1794552, 17002790.
64. Cheng HY, Papp JW, Varlamova O, Dziema H, Russell B, Curfman JP, Nakazawa T, Shimizu K, Okamura H, Impey S, Obrietan K. microRNA modulation of circadian-clock period and entrainment. Neuron 2007, 54(5):813-829. 10.1016/j.neuron.2007.05.017, 2590749, 17553428.
65. Bandres E, Cubedo E, Agirre X, Malumbres R, Zarate R, Ramirez N, Abajo A, Navarro A, Moreno I, Monzo M, Garcia-Foncillas J. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 2006, 5:29. 1550420, 16854228.
66. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM, Wang ZC, Brock JE, Richardson AL, Weinberg RA. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 2009, 137(6):1032-1046. 10.1016/j.cell.2009.03.047, 2766609, 19524507.
67. Lee LW, Zhang S, Etheridge A, Ma L, Martin D, Galas D, Wang K. Complexity of the microRNA repertoire revealed by next-generation sequencing. RNA 2010, 16(11):2170-2180. 10.1261/rna.2225110, 2957056, 20876832.
68. Valastyan S, Chang A, Benaich N, Reinhardt F, Weinberg RA. Activation of miR-31 function in already-established metastases elicits metastatic regression. Genes Dev 2011, 25(6):646-659. 10.1101/gad.2004211, 3059837, 21406558.
69. Wong QW, Lung RW, Law PT, Lai PB, Chan KY, To KF, Wong N. MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology 2008, 135(1):257-269. 10.1053/j.gastro.2008.04.003, 18555017.
70. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, Jacob S, Majumder S. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 2008, 283(44):29897-29903. 10.1074/jbc.M804612200, 2573063, 18708351.
71. Visone R, Russo L, Pallante P, De Martino I, Ferraro A, Leone V, Borbone E, Petrocca F, Alder H, Croce CM, Fusco A. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer 2007, 14(3):791-798. 10.1677/ERC-07-0129, 17914108.
72. Mercatelli N, Coppola V, Bonci D, Miele F, Costantini A, Guadagnoli M, Bonanno E, Muto G, Frajese GV, De Maria R, Spagnoli LG, Farace MG, Ciafre SA. The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS One 2008, 3(12):e4029. 10.1371/journal.pone.0004029, 2603596, 19107213.
73. le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A, Anile C, Maira G, Mercatelli N, Ciafre SA, Farace MG, Agami R. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J 2007, 26(15):3699-3708. 10.1038/sj.emboj.7601790, 1949005, 17627278.
74. Terasawa K, Ichimura A, Sato F, Shimizu K, Tsujimoto G. Sustained activation of ERK1/2 by NGF induces microRNA-221 and 222 in PC12 cells. FEBS J 2009, 276(12):3269-3276. 10.1111/j.1742-4658.2009.07041.x, 19438724.
75. Braun CJ, Zhang X, Savelyeva I, Wolff S, Moll UM, Schepeler T, Orntoft TF, Andersen CL, Dobbelstein M. p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res 2008, 68(24):10094-10104. 10.1158/0008-5472.CAN-08-1569, 2836584, 19074875.
76. Song B, Wang Y, Titmus MA, Botchkina G, Formentini A, Kornmann M, Ju J. Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol Cancer 2010, 9:96. 10.1186/1476-4598-9-96, 2881118, 20433742.
77. Georges SA, Biery MC, Kim SY, Schelter JM, Guo J, Chang AN, Jackson AL, Carleton MO, Linsley PS, Cleary MA, Chau BN. Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215. Cancer Res 2008, 68(24):10105-10112. 10.1158/0008-5472.CAN-08-1846, 19074876.
78. Takeuchi K, Ito F. EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors. FEBS J 2010, 277(2):316-326. 10.1111/j.1742-4658.2009.07450.x, 19922467.
79. Sanui A, Yotsumoto F, Tsujioka H, Fukami T, Horiuchi S, Shirota K, Yoshizato T, Kawarabayashi T, Kuroki M, Miyamoto S. HB-EGF inhibition in combination with various anticancer agents enhances its antitumor effects in gastric cancer. Anticancer Res 2010, 30(8):3143-3149.
80. Ebhardt HA, Tsang HH, Dai DC, Liu Y, Bostan B, Fahlman RP. Meta-analysis of small RNA-sequencing errors reveals ubiquitous post-transcriptional RNA modifications. Nucleic Acids Res 2009, 37(8):2461-2470. 10.1093/nar/gkp093, 2677864, 19255090.
81. Ebhardt HA, Fedynak A, Fahlman RP. Naturally occurring variations in sequence length creates microRNA isoforms that differ in argonaute effector complex specificity. Silence 2010, 1(1):12. 10.1186/1758-907X-1-12, 2901367, 20534119.
82. Fernandez-Valverde SL, Taft RJ, Mattick JS. Dynamic isomiR regulation in Drosophila development. RNA 2010, 16(10):1881-1888. 10.1261/rna.2379610, 2941097, 20805289.